Takeda Pharmaceutical (NYSE:TAK) Insider Sells $239,502.60 in Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Awny Samaan Botros Farajallah sold 14,006 shares of Takeda Pharmaceutical stock in a transaction on Monday, August 10th. The stock was sold at an average price of $17.10, for a total transaction of $239,502.60. Following the transaction, the insider directly owned 116,177 shares of the company’s stock, valued at $1,986,626.70. This represents a 10.76% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Price Performance

TAK stock opened at $17.64 on Friday. The company has a quick ratio of 0.62, a current ratio of 1.14 and a debt-to-equity ratio of 0.58. The firm has a market cap of $56.53 billion, a price-to-earnings ratio of 51.89 and a beta of -0.08. The company’s fifty day simple moving average is $16.57 and its 200 day simple moving average is $17.14. Takeda Pharmaceutical Co. has a 12-month low of $12.99 and a 12-month high of $18.90.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $0.56 earnings per share for the quarter. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%.The firm had revenue of $6.90 billion during the quarter. On average, analysts expect that Takeda Pharmaceutical Co. will post 1.5 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on TAK shares. Zacks Research raised shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 4th. Wall Street Zen upgraded Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Finally, Weiss Ratings downgraded Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, July 30th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Takeda Pharmaceutical currently has a consensus rating of “Hold”.

Hedge Funds Weigh In On Takeda Pharmaceutical

A number of hedge funds have recently added to or reduced their stakes in TAK. Renaissance Technologies LLC grew its position in Takeda Pharmaceutical by 14.2% during the first quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company’s stock worth $55,358,000 after buying an additional 370,800 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Takeda Pharmaceutical in the 4th quarter valued at about $998,000. Quantinno Capital Management LP boosted its position in shares of Takeda Pharmaceutical by 20.6% during the 1st quarter. Quantinno Capital Management LP now owns 1,289,326 shares of the company’s stock valued at $23,878,000 after acquiring an additional 219,999 shares during the last quarter. Bleakley Financial Group LLC boosted its position in shares of Takeda Pharmaceutical by 19.0% during the 1st quarter. Bleakley Financial Group LLC now owns 431,602 shares of the company’s stock valued at $7,993,000 after acquiring an additional 68,844 shares during the last quarter. Finally, Sivia Capital Partners LLC purchased a new position in shares of Takeda Pharmaceutical during the second quarter worth about $351,000. Institutional investors and hedge funds own 9.17% of the company’s stock.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.